242 related articles for article (PubMed ID: 35215860)
1. Combination of Novel Therapies for HDV.
Elazar M; Glenn JS
Viruses; 2022 Jan; 14(2):. PubMed ID: 35215860
[TBL] [Abstract][Full Text] [Related]
2. Emerging concepts for the treatment of hepatitis delta.
Elazar M; Glenn JS
Curr Opin Virol; 2017 Jun; 24():55-59. PubMed ID: 28475945
[TBL] [Abstract][Full Text] [Related]
3. Management of hepatitis delta: Need for novel therapeutic options.
Abbas Z; Abbas M
World J Gastroenterol; 2015 Aug; 21(32):9461-5. PubMed ID: 26327754
[TBL] [Abstract][Full Text] [Related]
4. HDV evolution-will viral resistance be an issue in HDV infection?
Tabernero D; Cortese MF; Buti M; Rodriguez-Frias F
Curr Opin Virol; 2018 Oct; 32():100-107. PubMed ID: 30415162
[TBL] [Abstract][Full Text] [Related]
5. Pathogenesis of and New Therapies for Hepatitis D.
Koh C; Heller T; Glenn JS
Gastroenterology; 2019 Jan; 156(2):461-476.e1. PubMed ID: 30342879
[TBL] [Abstract][Full Text] [Related]
6. Treatment of hepatitis D: an unmet medical need.
Caviglia GP; Rizzetto M
Clin Microbiol Infect; 2020 Jul; 26(7):824-827. PubMed ID: 32120043
[TBL] [Abstract][Full Text] [Related]
7. Preclinical assessment of antiviral combination therapy in a genetically humanized mouse model for hepatitis delta virus infection.
Winer BY; Shirvani-Dastgerdi E; Bram Y; Sellau J; Low BE; Johnson H; Huang T; Hrebikova G; Heller B; Sharon Y; Giersch K; Gerges S; Seneca K; Pais MA; Frankel AS; Chiriboga L; Cullen J; Nahass RG; Lutgehetmann M; Toettcher JE; Wiles MV; Schwartz RE; Ploss A
Sci Transl Med; 2018 Jun; 10(447):. PubMed ID: 29950446
[TBL] [Abstract][Full Text] [Related]
8. Investigational drugs in development for Hepatitis D.
Rizzetto M
Expert Opin Investig Drugs; 2017 Sep; 26(9):999-1005. PubMed ID: 28730878
[TBL] [Abstract][Full Text] [Related]
9. Hepatitis D - how is the fight against this foe going?
Loglio A; Segato S; Lampertico P
Expert Rev Clin Pharmacol; 2019 Mar; 12(3):169-171. PubMed ID: 30698044
[No Abstract] [Full Text] [Related]
10. What is the Path Forward to Treat Hepatitis Delta Virus?: Old Treatments and New Options.
Asselah T
Clin Liver Dis; 2023 Nov; 27(4):985-995. PubMed ID: 37778781
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic Strategies and New Intervention Points in Chronic Hepatitis Delta Virus Infection.
Guo Z; King T
Int J Mol Sci; 2015 Aug; 16(8):19537-52. PubMed ID: 26295228
[TBL] [Abstract][Full Text] [Related]
12. Treatment of delta hepatitis.
Gunsar F
Expert Rev Anti Infect Ther; 2013 May; 11(5):489-98. PubMed ID: 23627855
[TBL] [Abstract][Full Text] [Related]
13. Hepatitis D Virus and HBsAg Dynamics in the era of new Antiviral Treatments.
Shekhtman L; Duehren S; Etzion O; Cotler SJ; Dahari H
Curr Gastroenterol Rep; 2023 Dec; 25(12):401-412. PubMed ID: 37819559
[TBL] [Abstract][Full Text] [Related]
14. Hepatitis delta virus: From biological and medical aspects to current and investigational therapeutic options.
Alfaiate D; Dény P; Durantel D
Antiviral Res; 2015 Oct; 122():112-29. PubMed ID: 26275800
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of peginterferon alpha-2b in chronic hepatitis delta: relevance of quantitative RT-PCR for follow-up.
Castelnau C; Le Gal F; Ripault MP; Gordien E; Martinot-Peignoux M; Boyer N; Pham BN; Maylin S; Bedossa P; Dény P; Marcellin P; Gault E
Hepatology; 2006 Sep; 44(3):728-35. PubMed ID: 16941695
[TBL] [Abstract][Full Text] [Related]
16. Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial.
Wedemeyer H; Yurdaydin C; Hardtke S; Caruntu FA; Curescu MG; Yalcin K; Akarca US; Gürel S; Zeuzem S; Erhardt A; Lüth S; Papatheodoridis GV; Keskin O; Port K; Radu M; Celen MK; Idilman R; Weber K; Stift J; Wittkop U; Heidrich B; Mederacke I; von der Leyen H; Dienes HP; Cornberg M; Koch A; Manns MP;
Lancet Infect Dis; 2019 Mar; 19(3):275-286. PubMed ID: 30833068
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis D virus-specific cytokine responses in patients with chronic hepatitis delta before and during interferon alfa-treatment.
Grabowski J; Yurdaydìn C; Zachou K; Buggisch P; Hofmann WP; Jaroszewicz J; Schlaphoff V; Manns MP; Cornberg M; Wedemeyer H;
Liver Int; 2011 Oct; 31(9):1395-405. PubMed ID: 21762356
[TBL] [Abstract][Full Text] [Related]
18. Targeting Hepatitis D.
Rizzetto M
Semin Liver Dis; 2018 Feb; 38(1):66-72. PubMed ID: 29471567
[TBL] [Abstract][Full Text] [Related]
19. Dynamics of in vivo hepatitis D virus infection.
Goyal A; Murray JM
J Theor Biol; 2016 Jun; 398():9-19. PubMed ID: 27012516
[TBL] [Abstract][Full Text] [Related]
20. New insights into HDV persistence: The role of interferon response and implications for upcoming novel therapies.
Zhang Z; Urban S
J Hepatol; 2021 Mar; 74(3):686-699. PubMed ID: 33276031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
